EMA's CHMP upholds negative opinion on Omeros' Narsoplimab for TA-TMA

Omeros announced that the EMA's CHMP issued a negative opinion on its marketing authorization application for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), following re-examination of its original negative opinion from June. Omeros shares traded lower on the news, and its compassionate-use program has ended.

Detected & updated continuously · Source: Nebula